150 related articles for article (PubMed ID: 10996632)
21. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
22. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of melanoma.
Hersey P
Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S2-8. PubMed ID: 20482529
[TBL] [Abstract][Full Text] [Related]
25. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma.
Mackiewicz A; Wiznerowicz M; Roeb E; Nowak J; Pawlowski T; Baumann H; Heinrich PC; Rose-John S
Ann N Y Acad Sci; 1995 Jul; 762():361-73; discussion 373-4. PubMed ID: 7668537
[TBL] [Abstract][Full Text] [Related]
27. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
28. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
29. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
31. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
32. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.
Elliott GT; McLeod RA; Perez J; Von Eschen KB
Semin Surg Oncol; 1993; 9(3):264-72. PubMed ID: 8516615
[TBL] [Abstract][Full Text] [Related]
33. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
34. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapeutic approaches for the treatment of malignant melanoma.
Curiel-Lewandrowski C; Atkins MB
Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
[TBL] [Abstract][Full Text] [Related]
36. Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
Bright R; Coventry BJ; Eardley-Harris N; Briggs N
J Immunother; 2017 Jan; 40(1):21-30. PubMed ID: 27875387
[TBL] [Abstract][Full Text] [Related]
37. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of malignant melanoma.
Kadison AS; Morton DL
Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
40. Cancer vaccine--Antigenics.
BioDrugs; 2002; 16(1):72-4. PubMed ID: 11909004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
